Biotech’s IPO comeback; Trump’s tariff loophole for pharma

Biotech IPOs gain long-lost momentum, and pharma companies find a way around the White House’s harsh tariffs.

By PharmaVoice Staff • April 10, 2026

Will RFK Jr.’s peptide push bolster the gray market for obesity drugs?

With competition fierce in the weight loss space, a potential change to how the FDA classifies peptides could increase pressure in the market even more.

By Alivia Kaylor • April 10, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

One doctor helped kickstart US nuclear medicine’s new wave. Now he’s refining it.

Dr. Ebrahim Delpassand, founder and CEO of RadioMedix, played a pivotal role in advancing nuclear medicine as a new-generation cancer treatment, but his work is far from finished.

By Michael Gibney • April 9, 2026

Women have awaited a revolution in menopause. It hasn’t arrived.

Persistent barriers are still hindering drug development for a host of menopause symptoms.

By Kelly Bilodeau • April 8, 2026

Boehringer Ingelheim’s confident new leap in the obesity market

With weight loss candidates still in the clinic, the company has launched a health unit aimed at the flourishing therapeutic area.

By Alexandra Pecci • April 7, 2026

Tariffs are back. What does it mean now for pharma?

While the Trump administration has again levied large new tariffs, drugmakers willing to make deals could gain some relief.

By Kelly Bilodeau • April 6, 2026

AI’s next trick? Revealing new disease targets for drug R&D

A wave of AI-driven platforms bucks the traditional approach of hunting for new molecules and instead focuses on pinpointing the underlying cause of disease.

By Meagan Parrish • April 3, 2026

How Trump’s war in Iran is scrambling pharma’s shipping options

A blockade at one of the world’s largest shipping lanes could shape the way pharma companies think about manufacturing and distribution.

By Michael Gibney • April 2, 2026

Will Pfizer’s Lyme disease gamble pay off or set the space back?

As the disease spreads into new regions, the urgency for prevention is growing.

By Kelly Bilodeau • April 1, 2026

mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts

Research into areas like cancer could become collateral damage of a broader anti-mRNA push, according to a new study.

By Alexandra Pecci • March 31, 2026

Big Pharma goes nuts over food allergies — again

Novartis’ acquisition of Excellergy for up to $2 billion portends a potential new wave of medicines for food allergies.

By Michael Gibney • March 31, 2026

The FDA’s shame game

The agency is becoming more open about its criticisms of pharma companies and leaders, raising new privacy concerns in the industry.

By Kelly Bilodeau • March 30, 2026

Novo’s FDA voucher victory; biotech’s rigid glass ceiling

While Novo Nordisk collected a win through the FDA’s new voucher program, the initiative remains unpredictable and controversial.

By PharmaVoice Staff • March 27, 2026

Mixed signals cloud the orphan drug market

The field is making gains despite regulatory inconsistency, but rising competition from obesity candidates and evolving global pressures could erode orphan drugs’ market share.

By Kelly Bilodeau • March 25, 2026

Women in biotech hit a leadership plateau as board barriers persist

A new initiative from BioIndustry Association and AstraZeneca aims to boost representation on heavily dominated male boards.

By Alexandra Pecci • March 24, 2026

How AI is reshaping clinical trials

Human oversight remains crucial as the technology is leveraged in safety monitoring, boosting clinical trial diversity and more.

By Kelly Bilodeau • March 23, 2026

Gilead could potentially end HIV. But will it be able to?

After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.

By Meagan Parrish • March 20, 2026

Lilly’s manufacturing bet; hints of a biotech revival

Lilly is investing billions more into Chinese manufacturing — and other topics on our radar this week.

By PharmaVoice Staff • March 20, 2026

Novartis acquisition spin-off pioneers RNA therapeutics for the heart

The newly launched Atrium Therapeutics will focus on precision RNA therapeutics for rare, genetic cardiomyopathies.

By Alexandra Pecci • March 19, 2026

As Chinese biotechs recognize their value, the bargain era may be over

Rising average upfront payments signal that buyers see value in Chinese assets.

By Kelly Bilodeau • March 18, 2026

Federal court blocks RFK Jr.’s moves to upend US vaccine policy

HHS ignored established protocols in altering the childhood immunization schedule and overhauling a CDC panel, according to the ruling.

By Delilah Alvarado • March 17, 2026

VC sees early signs of a biotech market spring as long winter fades

The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.

By Michael Gibney • March 17, 2026

What’s at stake for Bayer in its Supreme Court showdown?

A key case being heard by the Supreme Court could help the large pharma put its Roundup litigation to rest.

By Kelly Bilodeau • March 16, 2026

340B: When the safest move can feel like no move at all. Why ‘waiting’ is no longer a viable strategy.

As 340B spend is surges, manufacturers need claims-level visibility to manage risk.

By Angie Franks, CEO of Kalderos • March 16, 2026

Novo regained weight loss footing in the pill arena — but Lilly is coming

Eli Lilly has run away with the GLP-1 market. But can Novo Nordisk maintain pole position in the oral space?

By Alivia Kaylor • March 13, 2026